Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GRANDE ALICIA						2. Issuer Name and Ticker or Trading Symbol <u>CATALYST PHARMACEUTICALS, INC.</u>								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
GRANDE ALICIA						CPRX	(]						Director			10% Owner			
(Last) (First) (Middle)					Ĺ								X Officer (give title Other (s below)				респу		
(Last) (First) (Middle) 355 ALHAMBRA CIRCLE, SUITE 1250						Date 0		Trans	saction (Mo	nth/D	ay/Year)		VP, Treasurer and CFO						
		101	/03/2	017															
(Street)				4. 1	If Ame	ndment, I	Date (of Original F	iled ((Month/Da		6. Individual or Joint/Group Filing (Check Applicable Line)							
CORAL FL 33134													X Form filed by One Reporting Person						
CADLES													Form filed by More than One Reporting Person						
(City) (State) (Zip)																			
		Tab	le I - Non	-Deriv	ativ	e Se	curities	s Ac	quired, I	Disp	osed o	f, or Bei	neficial	ly Owned					
1. Title of Security (Instr. 3) 2. Transact							2A. Deeme		3. 4. Securities Acquired (A)					5. Amou	6. Owne		7. Nature		
Date (Month/D					Day/Ye	ay/Year) Execution Date, if any (Month/Day/Yea			Code (Instr. 5)				ır. 3, 4 and	Beneficially (D)			direct E	of Indirect Beneficial Ownership	
						(MOIIIII/Day/Tea			` ` 			(A) or	Т	Reported Transaction(s)		(I) (Instr.		(Instr. 4)	
Code V Amount (A) or (D)													Price	(Instr. 3 and 4)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
	(e.g., puts, calls, warrants, options, convertible securities)															1			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day)	ate, T	I. Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Di or (I)	o. Wnership Orm: rect (D) Indirect (Instr. 4)	Beneficial Ownership (Instr. 4)	
													Amount or						
				c	Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Number of Shares						
Options to purchase common stock	\$1.13	01/03/2017			A		50,000		01/03/2018	3 0:	1/03/2024	Common Stock	50,000	\$0	670,000)	D		
Options to purchase common stock	\$1.13	01/03/2017			A		50,000		01/03/2019	0:	1/03/2024	Common Stock	50,000	\$0	720,000)	D		
Options to purchase									1						I				

Explanation of Responses:

/s/ Alicia Grande

01/04/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).